Printer Friendly

Printed from http://www.researchandmarkets.com/reports/1555416

Thought Leader Insight & Analysis Report - Crohn’s Disease, Ulcerative Colitis Q1 2010

Description:
In this last Gastroenterology Thought Leader Panel the publisher reported on key unmet needs in the treatment of Crohn’s disease and ulcerative colitis. In this report the publisher asks six internationally recognized experts in the treatment of inflammatory bowel disease to build on that, and engage with us in a thought exercise with the aim of ranking the most medically valuable initiatives in the developmental pipeline. Each thought leader was asked to identify the five agents that they were most looking forward to having available in the next few years - their “Fantasy Formulary.”

The Panel then turns to the more immediately commercially relevant question of comparing Simponi to other anti-TNF agents, next generation inhibitors of leukocyte trafficking to natalizumab and to each other, and both of these classes to p40 approaches.

The Panel was well represented by both very aggressive treaters, looking for stem cell transplants for everybody, and the very conservative treater who is looking to replace (whenever possible) biologicals and immunomodulators with more natural, homeopathic medicines. Each side makes their case.
Finally, Panelists comment on recent clinical setbacks for Humira in ulcerative colitis, and thoughts on Cimzia, 5-ASA products, new steroids, probiotics, oral small molecules (tasocitinib, apremilast, others) and newer biological approaches (e.g. IL-17, innate immunostimulators).
 
Contents:
Executive Summary
- “Fantasy Formulary” Survey – Methodology

Ground Rules and Scoring
- Results
- Table 1: Preferred Product Class
- Unmet needs
- Mucosal Healing / Antifibrotic
- Steroid-Sparing
- Pain / Neuropathy
- Reduce Serious Adverse Events
- Diagnostics
- New Therapeutic Approaches
- Key Findings
- Integrin / MAdCAM
- Tysabri (natalizumab; Biogen / Elan)
- vedolizumab (MLN-02 / MLN-0002; Takeda)
- rhuMAb-b7 (Genentech)
- PF-00547659 (Pfizer)
- p40: Anti-IL-12 / Anti-IL-23
- Stelara (ustekinumab / CNTO-1275; Centocor/Janssen-Cilag)
- briakinumab (ABT-874; Abbott)
- dual p40 / p19 MAb (IL-23 selective MAb; Merck / Schering-Plough)
- APG2305 (Allostera)
- Stem Cell Transplant
- Prochymal (Osiris Therapeutics)
- PDA-001; Celgene Cellular Therapeutics
- TNF
- Remicade (infliximab; Centocor)
- Humira (adalimumab; Abbott)
- Cimzia (certolizumab; UCB)
- Simponi; golimumab (Centocor / Schering-Plough / Merck)
- apremilast; CC-10004; (Celgene)
- AG011 (ActoGenix)
- Avaxia
- Steroid
- COLAL-PRED; prednisolone sodium metasulfobenzoate (Alizyme)
- Entocort; budesonide (Cosmo/Santarus)
- Probiotics
- E. coli nissle 1917 (Ardeypharm)
- IL-17
- AIN-457 (Novartis)
- JAK
- tasocitinib; CP-690550 (Pfizer)
- Immunomodulators
- laquinimod (Teva)
- Homeopathic
- curcumin
- Diet / Gluten Free
- Innate Immunostimulants
- Leukine; sargramostin; GMCSF (Bayer-Schering)
- CCR9
- Traficet-EN (CCX-282-B; ChemoCentryx/GSK)
- 5-ASA
- Asacol / Asacol-HD (Warner-Chilcott)
- Apriso (mesalamine; Salix)
- Lialda (mesalamine; Shire)

Thought-Leader Interviews
- Interview OHIID02405
- Interview OHIID02406
- Interview OHIID02407
- Interview OHIID02408
- Interview OHIID02409
- Interview OHIID02411
 
Companies Mentioned
Please see Brochure
 
Ordering:
Order Online - visit http://www.researchandmarkets.com/reports/1555416

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Page 1 of 2
Printed Wednesday, June 19, 2013
4:07:14 PM

Fax order form

To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net

Order information

Please verify that the product information is correct and select the format you require.

Product name

Thought Leader Insight & Analysis Report - Crohn’s Disease, Ulcerative Colitis Q1 2010

Web Address

http://www.researchandmarkets.com/reports/1555416

Office Code

OC8DIQQMMUWVXV

 

Report Formats

Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User EUR 5,737

Contact information

Please enter all the information below in block capitals.

Title:
Mr Mrs Dr Miss Ms Prof
First Name:
Last Name:
Email Address:
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2
Printed Wednesday, June 19, 2013
4:07:14 PM

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

American Express

Diners Club

Master Card

Visa

Cardholder's Name:
Cardholder's Signature:
Expiry Date:
/
Card Number:
CVV Security Code:
Issue date:
/ (Diners Club only)
 
Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Pay by Wire Transfer:

Please transfer funds to:

Account Number:
83313083
Sort Code:
98-53-30
Swift Code:
ULSBIE2D
IBAN Number:
IE78ULSB98533083313083
Bank Address:
Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
 

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)